TransMolecular, Inc. has received a Phase II Small Business Innovation Research (SBIR) grant to discover and develop pharmaceutical alternatives for treating neuropathic pain. The grant is worth approximately $760,000 over the next two years. “Neuropathic or chronic pain represents an underserved medical need. Ion channels have played an important part in the development of many Read more about Transmolecular Awarded Phase II Sbir Grant[…]